Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Carol A, Pamer"'
Autor:
Carol A. Pamer, Susan Lu, Andrew Winter, Robert Ball, Thomas Ly, Shahrukh Haider, Taxiarchis Botsis, Oanh Dang, David Milward, Sonja Brajovic
Publikováno v:
Journal of Biomedical Informatics. 83:73-86
Introduction The FDA Adverse Event Reporting System (FAERS) is a primary data source for identifying unlabeled adverse events (AEs) in a drug or biologic drug product's postmarketing phase. Many AE reports must be reviewed by drug safety experts to i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f50c995b189cbf028962143219a4292
https://doi.org/10.1016/j.jbi.2018.05.019
https://doi.org/10.1016/j.jbi.2018.05.019
Autor:
Sally Okun, Carol A. Pamer, David A. Blaser, Meaghan Zisk, Christine Caligtan, Marni Hall, Sonja Brajovic
Publikováno v:
JMIR Medical Informatics
Background: The availability of and interest in patient-generated health data (PGHD) have grown steadily. Patients describe medical experiences differently compared with how clinicians or researchers would describe their observations of those same ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a6b0b172fbbf1795a748e42d42e2f9d
http://europepmc.org/articles/PMC6123539
http://europepmc.org/articles/PMC6123539
Autor:
Sonja Brajovic, David A Blaser, Meaghan Zisk, Christine Caligtan, Sally Okun, Marni Hall, Carol A Pamer
BACKGROUND The availability of and interest in patient-generated health data (PGHD) have grown steadily. Patients describe medical experiences differently compared with how clinicians or researchers would describe their observations of those same exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fecc8de2bf5c3ab16b9dca57534ba84
https://doi.org/10.2196/preprints.9878
https://doi.org/10.2196/preprints.9878
Publikováno v:
J Am Med Inform Assoc
Objective: As the US Food and Drug Administration (FDA) receives over a million adverse event reports associated with medication use every year, a system is needed to aid FDA safety evaluators in identifying reports most likely to demonstrate causal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6add0d1f0549966b6f1a5b50d4034a7e
https://europepmc.org/articles/PMC7651970/
https://europepmc.org/articles/PMC7651970/
Autor:
Laura A. Governale, Andrew D. Mosholder, George Rochester, Yute Wu, Tarek A. Hammad, Carol A. Pamer, Sigal Kaplan
Publikováno v:
Pharmacoepidemiology and Drug Safety. 19:158-174
Purpose To determine if paroxetine versus non-paroxetine selective serotonin reuptake inhibitors (SSRIs) prescribing changed after the June 2003 FDA Paroxetine Public Health Advisory (PPHA) and if antidepressant and antipsychotic prescribing changed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62566b5fbac3ef516cb436f0b2e5f58e
https://doi.org/10.1002/pds.1886
https://doi.org/10.1002/pds.1886
Tardive Dyskinesia Risks and Metoclopramide Use Before and After U.S. Market Withdrawal of Cisapride
Publikováno v:
Journal of the American Pharmacists Association. 44:661-665
Objective To assess risk factors for tardive dyskinesia (TD) in spontaneousreports of metoclopramide and TD and evaluate metoclopramide prescribing patterns before and after withdrawal of cisapride from the market in the United States. Design Retrosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::633dd365884966d04bc649b5ed4a9a82
https://doi.org/10.1331/1544345042467191
https://doi.org/10.1331/1544345042467191
Publikováno v:
The patient. 8(4)
Opioid treatment agreements generally are used in pain treatment to delineate the terms and consequences of opioid use and abuse. The US Food and Drug Administration (FDA) Safe Use Initiative convened a multi-disciplinary working group with outside e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ba449d855323a73a53414cacc0de3d
https://pubmed.ncbi.nlm.nih.gov/25344927
https://pubmed.ncbi.nlm.nih.gov/25344927
Autor:
Sammie Beam, Jerry Phillips, Allen Brinker, Peter Honig, Carol Holquist, Carol A. Pamer, Laureen Y. Lee
Publikováno v:
American Journal of Health-System Pharmacy. 58:1835-1841
The types, causes, contributing factors, and patient demographics of fatal medication errors were reviewed. Case reports of medication errors from hospitals, ambulatory care settings, and patients' homes that were entered in FDA's Adverse Event Repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ef2989ffcc64a7f97e640652229e70c
https://doi.org/10.1093/ajhp/58.19.1835
https://doi.org/10.1093/ajhp/58.19.1835
Autor:
Carol A. Pamer, Jerry Phillips
Publikováno v:
Hospital Pharmacy. 35:1280-1286
The FDA Office of Postmarketing Drug Risk Assessment conducted a review of medication errors that have been reported with levothyroxine. These cases were obtained from the FDA Adverse Event Reporting System (AERS) database as well as the published me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44be9936bca8e5ab402892b1c41af9a0
https://doi.org/10.1177/001857870003501214
https://doi.org/10.1177/001857870003501214
Autor:
Carol A, Pamer, Tarek A, Hammad, Yu-Te, Wu, Sigal, Kaplan, George, Rochester, Laura, Governale, Andrew D, Mosholder
Publikováno v:
Pharmacoepidemiology and drug safety. 19(2)
To determine if paroxetine versus non-paroxetine selective serotonin reuptake inhibitors (SSRIs) prescribing changed after the June 2003 FDA Paroxetine Public Health Advisory (PPHA) and if antidepressant and antipsychotic prescribing changed after th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a00fe0a6c24a9af74aeac3ffc6e66a56
https://pubmed.ncbi.nlm.nih.gov/20049836
https://pubmed.ncbi.nlm.nih.gov/20049836